Stay updated with breaking news from Wendyn Davis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPDPatient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAEPatients...
CAMBRIDGE - Sage Therapeutics, Inc. and Biogen Inc. announced the U.S. Food and Drug Administration approved ZURZUVAETM 50 mg for adults with postpartum depression . ZURZUVAE is the first and...
Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45Mental health conditions are the leading cause of maternal mortality1 with PPD among the...
01.06.2022 - Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression (PPD), met its primary and all key ...
Zuranolone 50 mg demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpointsZuranolone 50 mg was generally well-tolerated and demonstrated a safety profile consistent with prior studiesPostpa...